Peritoneal dialysis-associated peritonitis caused by Brevundimonasaurantiaca.

J Infect ChemotherSep 29, 2026 (epub)

Wataru Mera, Tomoya Higuchi, Mayuka Higashi et al.

✦ AI-curated · Sources linked

Case in brief

A 55-year-old man with end-stage kidney disease receiving continuous ambulatory peritoneal dialysis developed peritonitis, with Brevundimonas aurantiaca recovered from two consecutive effluent cultures. Routine MALDI-TOF mass spectrometry did not reliably identify the organism; 16S rRNA gene sequencing established the species. Effluent cultures became negative during antimicrobial treatment, but cloudy effluent recurred one week after therapy ended. At recurrence, effluent and catheter cultures were negative, while one of two blood cultures grew Streptococcus agalactiae. The catheter was removed, and the patient improved without further peritonitis episodes.

What made this case unusual

The report describes PD-associated peritonitis due to B. aurantiaca, an organism for which this association had not previously been described. Species-level identification required 16S rRNA sequencing after routine MALDI-TOF mass spectrometry proved unreliable.

Diagnostic / clinical pearl

When routine MALDI-TOF mass spectrometry cannot reliably identify a Brevundimonas isolate from PD effluent, 16S rRNA gene sequencing can provide species-level identification.

Source

Published in J Infect Chemother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchOncology (Medical)

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations.

This international consensus guideline addresses curative-intent management of de novo metastatic nasopharyngeal carcinoma, a population historically treated with palliative intent.

Lancet OncolOct 29, 2026Read summary
Clinical ResearchHematology

Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.

This open-label, multicentre, randomised phase 3 trial compared decitabine plus busulfan-cyclophosphamide (DAC-BuCy) with BuCy conditioning before allogeneic HSCT in 130 patients aged 14–65 years with KMT2A-rearranged…

Lancet HaematolOct 30, 2026Read summary
Clinical ResearchPediatrics

Prone positioning and high-frequency oscillatory ventilation in early paediatric acute respiratory distress syndrome (PROSpect): an international, two-by-two factorial, response-adaptive, phase 3, randomised controlled trial.

PROSpect was an international, two-by-two factorial, phase 3 randomised controlled trial comparing prone with supine positioning and high-frequency oscillatory ventilation (HFOV) with conventional mechanical ventilation…

LancetOct 30, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.